| Similar Articles |
|---|
 |
The Motley Fool
January 28, 2008
Brian Lawler |
A Wing and a Prayer for Amgen Amgen announces data from its top pipeline drug candidate. Investors, take note.   |
The Motley Fool
February 9, 2010
Brian Orelli |
Bone Up On This Potential Blockbuster Amgen's denosumab passes another test on its way to potential blockbuster status. |
The Motley Fool
July 8, 2009
Brian Orelli |
Amgen Closes In on a Home Run Amgen already had a ball flying high above the outfield in its osteoporosis treatment, denosumab, but yesterday's clinical trial results were the wind that could push it out of the park. |
The Motley Fool
June 2, 2010
Brian Orelli |
Little Surprise. Big Stock Move. Investors like Amgen's early approval;shares are up 9% today, well ahead of the overall market. |
The Motley Fool
December 26, 2006
Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year. |
The Motley Fool
October 26, 2010
Brian Orelli |
Thank Goodness for Amgen's New Kids The old drugs are dragging down Amgen's growth. |
The Motley Fool
June 30, 2010
Brian Orelli |
Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth? |
The Motley Fool
August 25, 2008
Brian Lawler |
Amgen Gets Its FDA Response Amgen investors can finally breathe a little sigh of relief after the biopharma giant announces that the Food and Drug Administration has finally approved its blood disorder drug. |
The Motley Fool
February 9, 2011
Luke Timmerman |
Amgen Pushes Ahead With "Son of Dmab" for Treating Bones Is there more to Amgen than "Dmab"? |
The Motley Fool
July 30, 2007
Brian Lawler |
Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note. |
The Motley Fool
November 19, 2010
Brian Orelli |
One Drug, Two Names, Two Wildly Different Prospects Amgen double speaks for increased sales. |
The Motley Fool
September 28, 2006
Brian Lawler |
Amgen Secures Its Future FDA approval for the company's colorectal cancer drug is good news for its future prospects. Investors, take note. |
The Motley Fool
April 21, 2011
Luke Timmerman |
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis. |
Pharmaceutical Executive
October 1, 2008
Joanna Breitstein |
The D-Mab Men Amgen's salvation just may be denosumab. We sit down to talk with the head scientists driving the drug for the multi-billion dollar osteoporosis market |
The Motley Fool
July 21, 2008
Brian Lawler |
Amgen Rolls the Dice The Food and Drug Administration's impending ruling will determine the drugmaker's near-term fate. Investors, take note. |
BusinessWeek
August 13, 2009
Arlene Weintraub |
Amgen's Bone-Loss Drug Faces Marketing Hurdles Amgen is likely to receive FDA approval for denosumab, its new biologic bone-loss drug, but it may be a hard sell against cheaper generics. |
BusinessWeek
January 14, 2010
Rob Waters |
Amgen: Strengthening Bones, Weakening Cancer? Regulators may soon approve an Amgen drug, denosumab, for osteoporosis, but the payoff could be in oncology. |
The Motley Fool
August 19, 2009
Brian Orelli |
Them's the Breaks for Lilly The drugmaker cuts its losses after a disappointing trial on an osteoporosis drug. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
The Motley Fool
August 11, 2010
Brian Orelli |
Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
July 21, 2006
Brian Lawler |
Amgen's Little Helpers Sluggish earnings are offset by promising drugs in the pipeline. The bottom line with Amgen is that it is one of the best-run biotechs, period. Investors, take note. |
The Motley Fool
April 28, 2008
Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings. |
The Motley Fool
October 19, 2009
Brian Orelli |
Still Waiting for Its Blockbuster Amgen announces a Food and Drug Administration delay for its long-awaited osteoporosis drug, Prolia, its treatment for postmenopausal osteoporosis. |
The Motley Fool
September 17, 2008
Brian Orelli |
Will Denosumab Strengthen Amgen's Bones? Recently passing its phase 3 trial will help get denosumab on the market. But two big questions remain: how well it worked, and whether anyone will buy it, given the drug's plentiful rivals. |
BusinessWeek
May 15, 2006
Arlene Weintraub |
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors. |
The Motley Fool
July 28, 2009
Brian Orelli |
Amgen Secures Its Future Earnings and a marketing partnership -- oh my. |
The Motley Fool
January 29, 2007
Brian Lawler |
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap. |
The Motley Fool
April 24, 2007
Brian Lawler |
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices. |
The Motley Fool
May 29, 2007
Brian Lawler |
Amgen Is Vexed The European Union medical authority says no to Amgen's cancer compound. Investors, take note. |
The Motley Fool
June 7, 2007
Brian Lawler |
Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline. |
The Motley Fool
November 9, 2006
Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note. |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
The Motley Fool
October 20, 2005
Brian Gorman |
Amgen's Drive to Diversify The drugmaker pulled in impressive results with its current portfolio, but a drug in late-stage testing could make the company even more attractive to investors. |
The Motley Fool
September 25, 2007
Brian Lawler |
Amgen's European Adventures The European Medicines Agency announces that it has reversed its decision on Amgen's cancer drug Vectibix, allowing it on the market for a limited patient population. Investors, take note. |
The Motley Fool
November 26, 2010
Brian Orelli |
Black Friday Biotech Bargains Drugmakers on sale. |
The Motley Fool
October 24, 2008
Brian Orelli |
Amgen's Back Shares of Amgen are up 40% from their lows in March. And for good reason. |
The Motley Fool
August 30, 2010
Brian Orelli |
Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help. |
The Motley Fool
July 8, 2008
Brian Lawler |
Blockbuster Drugs Bound for Extinction? One of the biggest classes of prescription drugs, those for diabetes treatments, faces tougher FDA standards. |
The Motley Fool
August 31, 2010
Brian Orelli |
Drugmakers May Lose a Back Door for Drug Approval Non-inferiority trials may be inferior. |
The Motley Fool
February 26, 2010
Brian Orelli |
Boning Up on Pfizer's Drug Fablyn looks OK on paper, but that isn't going to cut it in the crowded osteoporosis market. |
The Motley Fool
October 7, 2004
Charly Travers |
Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful. |
The Motley Fool
February 26, 2011
Brian Orelli |
FDA Applications and a Look Ahead It isn't pretty. |
The Motley Fool
January 7, 2010
Brian Orelli |
Warning: Potential Anemic Growth Ahead Anemia-drug makers get more scrutiny from the FDA. |
The Motley Fool
August 14, 2009
Brian Orelli |
Amgen Close to Scoring Big Amgen gets good-enough results from a FDA panel. |
The Motley Fool
June 12, 2007
Brian Lawler |
ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label. |
The Motley Fool
July 30, 2010
Brian Orelli |
On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually. |
The Motley Fool
August 1, 2008
Brian Lawler |
Is $60 a Share Enough for ImClone? Bristol-Myers Squibb announced a $60-per-share offer for ImClone Systems, but are shareholders going to go for the deal? |
The Motley Fool
January 29, 2007
Brian Lawler |
ImClone Fights The Competition The drug developer's performance has been alright, but the competition is heating up. Investors, take note. |
The Motley Fool
April 27, 2007
Brian Lawler |
Tracking ImClone The biopharmaceutical releases first-quarter financial results. Investors, take note. |
